[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"neuro-ophthalmology\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:neuro-ophthalmology":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,37,73],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":26,"lastUpdatePostDateStruct":27,"startDateStruct":30,"completionDateStruct":32,"leadSponsor":34,"locationsCount":5},"100397141","diagnostic-accuracy-of-optimized-diffusion-weighted-imaging-for-detecting-anterior-ischemic-optic-neuropathy-100397141",false,"NCT04451265","Diagnostic Accuracy of Optimized Diffusion-Weighted Imaging for Detecting Anterior Ischemic Optic Neuropathy","DACODAC","Inclusion Criteria:\n\n* Patient over 18 years old\n* Patient with suspected NOIA, evoked after clinical examination by a specialized ophthalmologist\n* For which a brain and visual MRI is planned\n* Express consent to participate in the study\n* Affiliate or beneficiary of a Social Security scheme\n\nExclusion Criteria:\n\n* Contraindication to MRI (electrical device, metallic foreign body, claustrophobia)\n* Patient benefiting from a legal protection measure\n* Pregnant or breastfeeding woman","ALL","18 Years",{"count":19,"type":20},250,"ESTIMATED","OBSERVATIONAL","The patient presents to the ophthalmological emergencies and \u002F or to the internal medicine department. NOIA clinical discovery Patient referred in radiology for brain and visual MRI. The two sequences added by the research (8 minutes) will be added to that of the treatment.",[24],"Neuro-Ophthalmology","RECRUITING","2025-12-30",{"date":28,"type":29},"2026-01-05","ACTUAL",{"date":31,"type":29},"2022-10-26",{"date":33,"type":20},"2028-03",{"name":35,"class":36},"Fondation Ophtalmologique Adolphe de Rothschild","NETWORK",{"id":38,"slug":39,"hasResults":11,"nctId":40,"briefTitle":41,"officialTitle":42,"acronym":43,"eligibilityCriteria":44,"healthyVolunteers":45,"sex":16,"minAge":46,"maxAge":4,"enrollmentInfo":47,"targetDuration":49,"studyType":21,"phases":4,"briefSummary":50,"conditions":51,"keywords":52,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":5},"100612794","safety-and-normative-data-with-neos-100612794","NCT07258212","Safety and Normative Data With Neos™","Safety and Normative Data With Neos™, in Healthy Volunteers, Children and Patient Populations With Ophthalmological or Neurological Disease","neos-SNOW","Inclusion Criteria Healthy Volunteers:\n\n* Age \\> 3\n* Informed consent by participant and\u002For legal representative documented per signature\n* Snellen visual acuity ≥ +0.1 LogMAR, with correction, on both eyes\n* Refractive error between -10 and +5 diopters, on both eyes\n\nExclusion Criteria Healthy Volunteers:\n\n* Known ophthalmological, neurological or vestibular disease\n* Current medication\u002Fdrugs that could potentially influence performance in ocular motor tasks and\u002For compliance in the judgement of the investigator (e.g. benzodiazepines, alcohol, or stimulants)\n* Stimulative medication (e.g. with Ritalin®)\n* Known substance abuse\n\nInclusion Criteria Patients:\n\n* Age \\> 3\n* Informed consent by participant and\u002For legal representative, designated trusted person or next of kin, documented per signature\n* Refractive error between -10 and +5 diopters, on both eyes\n* Known ophthalmological or neurological disease\n\nExclusion Criteria Patients:\n\n* Visual acuity in one or both eyes \\\u003C +1.3 LogMAR\n* Incapacity to understand and comply with the examination in the opinion of the investigator (e.g. due to very advanced dementia, with failure to comply with easy experimental instructions and tasks)\n* Known substance abuse",true,"3 Years",{"count":48,"type":20},200,"1 Day","The goal of this clinical study is to collect standard data for the medical device neos™.\n\nneos™ is a system that shows images and measures the resulting eye movements and pupil size.\n\nCollecting standard data involves three steps. First it is checked if neos™ eye-tracking works well. Eye-tracking means recording where a person is looking. After that it is checked if participants look at the images shown in neos™ as planned. Finally the eye movements and the pupil size are measured. This is done in healthy volunteers including children and persons with eye and brain problems.\n\nParticipants in the study will wear a virtual reality headset. The screens in the headset will show different images. Cameras in the headset will record eye movements and pupil size. This will take about 15 minutes. During these 15 minutes the investigator looks at the following behaviors of the participants eyes:\n\n* Where are the eyes looking\n* How do the pupils react to light and darkness\n* How do the eyes move\n* How much can the participant see from the corner of their eyes\n* How well are the eyes working together",[24],[53,54,55,56,57,58,59,60,61,62],"Virtual reality","Visual field","Ocular alignment","Afferent pupillary function","Efferent pupillary function","Smooth pursuit","Saccades","Gaze holding","Fusional amplitude","Normative data","2025-11-27",{"date":65,"type":29},"2025-12-02",{"date":67,"type":29},"2024-03-07",{"date":69,"type":20},"2026-06",{"name":71,"class":72},"machineMD AG","INDUSTRY",{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":16,"minAge":80,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":83,"conditions":84,"keywords":90,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":4},"100598776","optic-nerve-head-evaluation-through-multimodal-blood-flow-analysis-a-prospective-observational-multi-center-study-100598776","NCT07075887","Optic Nerve Head Evaluation Through Multimodal Blood Flow Analysis: a Prospective Observational, Multi-center Study","FlowONH","Inclusion Criteria:\n\n* Participant (or parents\u002Flegal representative\u002Ftutor for minors) is willing and able to give informed consent for participation in the study\n* patients affected by acute ONH edema (NAION, papilledema, optic neuritis)\n* patients affected by acute pseudoedema (LHON)\n* patients affected by chronic pseudoedema (LHON, ODD)\n* patients affected by chronic ONH neuropathies (NTG, DOA, WS) non- affected eyes in each optic neuropathy patient\n\nExclusion Criteria:\n\n* any other ONH disease or neurological \u002Fretinal disease impairing the evaluation of the ONH;\n* evidence of media opacities affecting the quality of the vascular assessment;\n* patients affected Alzheimer\u002FParkinson disease will be considered separately","12 Years",{"count":82,"type":20},70,"OCT-A and eco-colordoppler are technologies which enable optic nerve head (ONH) blood perfusion detection. The aim of the study is to assess ONH vascular and structural components in optic neuropathies with and without ONH edema or pseudo-edema with OCT-A, and analyze ONH blood-flow with eco-colordoppler.",[24,85,86,87,88,89],"Optic Neuropathies","Optic Atrophy, Hereditary, Leber","Optic Neuropathy, Anterior Ischemic","Optic Disc Drusen","Normal Tension Glaucoma (NTG)",[91,92,93],"oct-a","ecocolordoppler","optic neuropathies","NOT_YET_RECRUITING","2025-07-10",{"date":97,"type":29},"2025-07-20",{"date":99,"type":20},"2025-10",{"date":101,"type":20},"2028-10",{"name":103,"class":104},"Barboni","OTHER"]